Q-omics provides the consensus-scored ZFP82 profile across patient tissues and cancer cell-line models. ZFP82 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZFP82 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZFP82 RNA expression shows 20,093 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where ZFP82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP82 survival associations across molecular data types. ZFP82 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP82 RNA expression–survival associations across cancer types. High ZFP82 expression shows unfavorable associations in LGG, but favorable associations in UVM, KIRC, PAAD, HNSC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZFP82 RNA expression.
This table summarizes ZFP82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZFP82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP82 shows lower tumor expression in THCA, KICH, COAD and UCEC and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher ZFP82 RNA expression in normal versus tumor tissue (log2 FC = −0.780, t-test p < 0.001).
This table shows molecular features associated with ZFP82 in patient tissues and cancer cell lines. In patient samples, ZFP82 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFP82 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
